Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 61,767	$ 64,380
Short-term marketable securities	257,069	275,324
Assets held for sale	1,571
Prepaid expenses and other current assets	4,404	5,308
Total current assets	324,811	345,012
Long-term marketable securities	12,441	28,388
Operating lease right-of-use assets	22,933	23,481
Restricted cash	567	567
Property and equipment, net	1,112	11,295
Other non-current assets	93	5,311
Total assets	361,957	414,054
Current liabilities:
Accounts payable	4,233	2,441
Accrued clinical and research and development expenses	5,565	12,521
Accrued expenses and other current liabilities	2,336	9,437
Accrued restructuring costs	36,920
Operating lease liabilities, current	2,498	628
Total current liabilities	51,552	25,027
Operating lease liabilities, non-current	27,948	28,798
Total liabilities	79,500	53,825
Stockholders' equity:
Common stock	46	46
Additional paid-in capital	679,461	672,540
Accumulated other comprehensive income	96	291
Accumulated deficit	(397,146)	(312,648)
Total stockholders' equity	282,457	360,229
Total liabilities and stockholders' equity	$ 361,957	$ 414,054